Ziltivekimab

Key takeaways

Ziltivekimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Ziltivekimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Ziltivekimab from memory before moving on to harder problems.

Reference excerpt

Ziltivekimab is an investigational new drug being developed by Novo Nordisk for the treatment of various inflammatory diseases. It is a fully human monoclonal antibody that targets interleukin 6 (IL-6). Ziltivekimab is under investigation for its potential to reduce inflammation in conditions such as cardiovascular disease, chronic kidney disease (CKD), heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF), and anemia of inflammation. Administered subcutaneously or intravenously, ziltivekimab has demonstrated potential in clinical trials by lowering inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) and improving anemia-related parameters in CKD patients. As of May 2025, ziltivekimab remains investigational and has not been approved for clinical use. It is currently being evaluated in ongoing phase 2 and phase 3 clinical trials.

Medical use Ziltivekimab is being developed to manage inflammatory conditions associated with elevated IL-6 levels, including cardiovascular disease, CKD, heart failure (HFpEF/HFmrEF), and anemia of inflammation. It aims to reduce systemic inflammation, as measured by biomarkers like hsCRP, serum amyloid A, and fibrinogen, which are linked to adverse outcomes in these conditions. In CKD, ailtivekimab has shown potential to improve anemia by reducing IL-6-mediated hepcidin expression, decreasing reliance on erythropoiesis-stimulating agents (ESAs). It is also under investigation for reducing cardiovascular events in high-risk patients, such as those post-myocardial infarction or with atherosclerotic disease. As of May 2025, it is not approved for any indication and is limited to clinical trial settings.

Mechanism of action Ziltivekimab is a human IgG1, κ monoclonal antibody that binds to the IL-6 ligand, preventing its interaction with the IL-6 receptor and inhibiting downstream inflammatory signaling. By neutralizing IL-6, it reduces the production of acute-phase reactants like hsCRP, serum amyloid A, and fibrinogen, which contribute to systemic inflammation. In CKD, Ziltivekimab lowers hepcidin levels, improving iron metabolism and alleviating anemia of inflammation. Its targeted IL-6 inhibition distinguishes it from IL-6 receptor blockers like tocilizumab, potentially offering a different safety profile with fewer immunosuppressive effects.

Clinical trials

Phase 1/2 trial in hemodialysis patients A phase 1/2, randomized, double-blind, placebo-controlled trial (NCT02868229) evaluated Ziltivekimab in 61 hemodialysis patients with chronic kidney disease (CKD), elevated interleukin-6 (≥4 pg/mL), and a TMPRSS6 gene polymorphism (rs855791) associated with IL-6–mediated inflammation. Patients received placebo or Ziltivekimab (2, 6, or 20 mg) intravenously every two weeks for 12 weeks. The trial assessed safety, pharmacokinetics, and pharmacodynamic endpoints, including inflammatory markers, iron parameters, and erythropoiesis-stimulating agent (ESA) usage.

RESCUE trial The phase 2 RESCUE trial (NCT03926117) was a double-blind, randomized, placebo-controlled study that enrolled 264 patients with CKD stage 3–5 and high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L. Patients received placebo or subcutaneous Ziltivekimab (7.5, 15, or 30 mg) every four weeks for up to 24 weeks. The trial evaluated changes in hsCRP, hemoglobin levels, iron metabolism biomarkers, and safety outcomes.

RESCUE-2 trial The RESCUE-2 trial (NCT04626505), a phase 2, randomized, double-blind study in Japan, enrolled 36 adults with CKD stage 3–5 and hsCRP ≥2 mg/L. Participants received placebo or Ziltivekimab (15 or 30 mg) subcutaneously at weeks 0, 4, and 8. The study assessed changes in hsCRP, serum amyloid A, fibrinogen, lipid profiles, and treatment-emergent adverse events.

HERMES and ZEUS trials The ongoing HERMES trial (NCT05636176) is evaluating monthly subcutaneous Ziltivekimab (15 mg) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF or HFmrEF). The primary endpoints include cardiovascular death, heart failure hospitalization, and urgent visits. The ZEUS trial (NCT05021835), a phase 3 study, is assessing Ziltivekimab's effects on cardiovascular outcomes—including myocardial infarction and stroke—in patients with established cardiovascular disease, CKD, and hsCRP ≥2 mg/L. The ZEUS trial failed to meet its primary endpoint, showing no clinically significant reduction in major adverse cardiac events (MACE), despite successfully lowering IL-6 and other inflammatory biomarkers. Serious infections were more common in the ziltivekimab group, with overall rates of serious adverse events being comparable across groups.

Safety and side effects Ziltivekimab has been well-tolerated in trials, with no dose-limiting toxicities reported. In the phase 1/2 hemodialysis trial, four treatment-emergent deaths occurred, but no clear causal link to Ziltivekimab was established. The RESCUE and RESCUE-2 trials reported no significant increases in thrombocytopenia, neutropenia, or infections compared to placebo, unlike other IL-6 inhibitors like tocilizumab. A small, statistically significant increase in triglycerides was noted in RESCUE-2, but cholesterol profiles remained unaffected.

History and legal status Ziltivekimab was initially developed by Corvidia Therapeutics and later acquired by Novo Nordisk, and is in phase 2 and 3 trials for cardiovascular disease, CKD, and heart failure.

Worked examples

Example 1 — a first encounter with Ziltivekimab

Start with the simplest possible case. Write down what Ziltivekimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Ziltivekimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Ziltivekimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Ziltivekimab

In research: Ziltivekimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Ziltivekimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Ziltivekimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Anti-interleukin monoclonal antibodies, Experimental monoclonal antibodies, so understanding it makes those chapters shorter.
In everyday life: Look for Ziltivekimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Ziltivekimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Ziltivekimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Ziltivekimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Ziltivekimab in simple terms?

Ziltivekimab is an investigational new drug being developed by Novo Nordisk for the treatment of various inflammatory diseases. It is a fully human monoclonal antibody that targets interleukin 6 (IL-6).

Why does Ziltivekimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Ziltivekimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Ziltivekimab.